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Von Willebrand disease (VWD) can be associated with signiﬁcant morbidity. Patients with
VWD can experience bruising, mucocutaneous bleeding, and bleeding after dental and
surgical procedures. Early diagnosis and treatment are important to minimize the risk of
these complications. Several bleeding assessment tools (BATs) have been used to quantify
bleeding symptoms as a screening tool for VWD. We systematically reviewed diagnostic test
accuracy results of BATs to screen patients for VWD. We searched Cochrane Central,
MEDLINE, and EMBASE for eligible studies, reference lists of relevant reviews, registered
trials, and relevant conference proceedings. Two investigators screened and abstracted
data. Risk of bias was assessed using the revised tool for the quality assessment of diagnostic
accuracy studies and certainty of evidence using the Grading of Recommendations
Assessment, Development and Evaluation framework. We pooled estimates of sensitivity and
speciﬁcity. The review included 7 cohort studies that evaluated the use of BATs to screen
adult and pediatric patients for VWD. The pooled estimates for sensitivity and speciﬁcity
were 75% (95% conﬁdence interval, 66-83) and 54% (29-77), respectively. Certainty of
evidence varied from moderate to high. This systematic review provides accuracy estimates
for validated BATs as a screening modality for VWD. A BAT is a useful initial screening test to
determine who needs speciﬁc blood testing. The pretest probability of VWD (often
determined by the clinical setting/patient population), along with sensitivity and speciﬁcity
estimates, will inﬂuence patient management.
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Introduction
Von Willebrand factor (VWF) is a hemostatic protein that facilitates
platelet adhesion and aggregation in addition to stabilizing coagulation
factor VIII (FVIII).1-4 Qualitative or quantitative abnormalities in VWF
can lead to von Willebrand disease (VWD).5 The reported prevalence
of VWD is up to 1% in the general population6,7 with a symptomatic
prevalence of 1 in 1000 at the level of primary care.8,9 This prevalence may be up to 15% in women with chronic heavy menstrual
bleeding, making VWD the most common inherited bleeding
disorder.10,11

In addition to variation in VWD management, there is limited awareness within the VWD community on the best clinical practice for
screening and diagnosis.14 The aim of this systematic review is to
determine the accuracy of bleeding assessment tools (BATs) and
other nonstandard bleeding inventories as screening tests for VWD,
which can be used to inform a combined strategy for diagnosis.
Test accuracy estimates obtained in this systematic review were
used to inform evidence-based recommendations on diagnostic strategies for the recently published clinical practice guidelines on VWD,
developed by a combined effort from the American Society of Hematology, the International Society on Thrombosis and Haemostasis
(ISTH), the National Hemophilia Foundation, the World Federation
of Hemophilia, and the University of Kansas Medical Center.15 The
guidelines aim to inform all stakeholders on essential issues in which
there is variation or uncertainty in clinical practice and will support
decision-making in the context of patients’ values and preferences.

Methods
Search strategy and data sources
We searched MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials from inception through August 2019. We also
manually searched the reference lists of relevant articles and existing
reviews. The search was limited to studies reporting data for accuracy
of diagnostic tests. The complete search strategy is available in supplement 1. The prespeciﬁed protocol for this review is registered with
PROSPERO (CRD42020147977). This review is reported in accordance with Preferred Reporting Items for Systematic reviews and
Meta-Analyses for diagnostic test accuracy guidelines.16

Study selection
We used the following eligibility criteria.
Studies. We included studies reporting data on diagnostic test
accuracy (cohort studies, cross-sectional studies) for VWD.
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Index tests for diagnosis. BATs and nonstandardized testing.
We did not exclude studies based on the timing of when the index
test was conducted.
Reference standards. If a reference diagnostic test was not conducted, we accepted clinical follow-up as a reference standard.
Exclusion criteria. Although studies reporting on patients with
VWD as well as other bleeding disorders were eligible for inclusion,
we excluded studies in which .80% of the study population included
a different bleeding disorder. When possible, we extracted data separately for patients with VWD from these studies. We also excluded
studies that did not provide sufﬁcient data to determine test accuracy
(sensitivity and speciﬁcity), studies only available as an abstract, studies with sample size fewer than 10 patients, and studies that used an
unsuitable reference standard.

Screening and data extraction
Independent reviewers conducted title and abstract screening and
full-text review in duplicate to identify eligible studies. Two reviewers
completed data extraction independently and in duplicate and data
were veriﬁed by a third reviewer (M.A.K.). Disagreements were
resolved by discussion to reach consensus, in consultation with 2
expert clinician scientists (N.C. and P.J.). We extracted data about
general study characteristics (authors, publication year, country, study
design), diagnostic index test and reference standard, prevalence of
VWD, and parameters to determine test accuracy (ie, sensitivity and
speciﬁcity of the index test).

Risk of bias and certainty of evidence
We conducted the risk of bias assessment for diagnostic test accuracy studies using the Quality Assessment of Diagnostic Accuracy
Studies-2 revised tool.17 We used the Grading of Recommendations
Assessment, Development and Evaluation framework to assess overall certainty by evaluating the evidence for each outcome on the following domains: risk of bias, imprecision, inconsistency,
indirectness, and publication bias.18,19

Data synthesis
When feasible, we combined the accuracy estimates from individual
studies quantitatively (ie, pooled) for each test using OpenMetaAnalyst.20 We conducted a bivariate analysis for pooling sensitivity and
speciﬁcity for each of the test comparisons to account for variation
within and between studies. Forest plots were created for each comparison. The Breslow-Day test was used to measure the percentage
of total variation across studies because of heterogeneity (I2); however, the results did not inﬂuence our judgment about inconsistency
from the known methodological limitations of I2 in test accuracy
reviews.21
Diagnostic strategies for VWD are based on assessment of the pretest probability for individual patients, which provides an estimate of
the expected prevalence of VWD at a population level. We calculated
the absolute differences in effects for each comparison as true positives, true negatives, false positives, and false negatives. Here, we
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Patients with VWD may experience easy bruising and bleeding, especially mucocutaneous bleeding such as epistaxis, oral cavity, and
heavy menstrual bleeding as well as bleeding after childbirth and dental and surgical procedures. The clinical presentation varies greatly
and the bleeding phenotype may change throughout a person’s life,
leading to different management plans, depending on the type and
subtype of VWD.12,13 Three types of VWD have been deﬁned
depending on the type of abnormality in VWF. Type 1 VWD occurs
because of partial quantitative deﬁciency in VWF as a result of a deﬁcit
in synthesis or increased clearance, type 2 VWD is commonly divided
into 4 major qualitative variants (types 2A, 2B, 2M, and 2N), and in
type 3 VWD there is an absence of VWF production.4,7,10

Participants. Patients suspected of having VWD of any age, presenting to inpatient or outpatient settings.

Table 1. Characteristics of included studies
Study design

No. of
patients

First author

Year

Patient selection

Index test

Reference standard

Bowman

2008

Cohort with DTA
results for adults

217

Unrelated adults (age 20-88 y)
recruited from primary care
clinics investigated for VWD
type 1 (35 male, 65 female)

Deforest

2015

Cohort with DTA
results for adults

64

Adult patients (age 18-73 y)
Self-BAT: ISTH-BAT was converted to a Laboratory workup including
referred for the ﬁrst time to a
grade 4 reading level to produce the
CBC, INR/PT/PTT,
hematologist because of a
ﬁrst version of the Self-BAT, which
thrombin time, ﬁbrinogen,
problem with bleeding or
was then optimized to ensure
ferritin, ABO blood group,
bruising (11 male, 53 female)
agreement with the ISTH-BAT. A
VWF:Ag, VWF:RCo,
normal bleeding score was 0 to 15 for FVIII:C, and VWF
females and 0 to 13 for males
multimers

Philipp

2008

Cohort with DTA
results for adults

146

Females (age 13-55 y) receiving a 12-page questionnaire based on the
Laboratory workup including
physician diagnosis of heavy
bleeding symptoms found signiﬁcant
VWF:Ag and VWF:RCo
menstrual bleed at the faculty
in women with WWD. A screening
gynecology practice of UMDNJ- tool was positive if 1 of 4 criteria were
Robert Wood Johnson Medical
met: severity of heavy menstrual
School or collaborating
period, history of treatment of anemia,
community gynecology and
excess bleeding after challenges
pediatric practices
including dental surgery, surgery and
delivery, family history of bleeding
disorder

Bidlingmaier

2012

Cohort with DTA
results for children

100

Children (age 1-17 y), 44 with a Quantitative ISTH child bleeding score
and the qualitative ITEM analysis. A
positive bleeding history, 29
referred because of an isolated bleeding score $2 was considered
abnormal
APTT prolongation, and 27
because of a positive family
history of bleeding

Bowman

2009

Cohort with DTA
results for children

151

Children (age ,18 y) from the
PBQ: The MCMDM-1VWD Bleeding
Laboratory workup including
waiting room of the Childrens
Questionnaire was modiﬁed by
VWF:RCo, VWF:Ag,
Outpatient Centre, the Hotel
including pediatric-speciﬁc bleeding
FVIII:C, VWF multimers,
Dieu Hospital in Kingston,
symptoms in the “other” category. A
genetic testing
Ontario, investigated for VWD
bleeding score $2 was considered
because of a personal history of abnormal
hemorrhagic symptoms and/or
a family history of VWD and/or
for preoperative screening

Malec

2016

Cohort with DTA
results for children

193

Children (age ,11 y) referred to anComposite score that was considered Laboratory workup including
outpatient bleeding disorders
positive when 2 of 4 criteria were
VWF:RCo, VWF:Ag,
clinic for evaluation of VWD
positive: Tosetto bleeding score Z1;
FVIII:C, VWF multimers
and/or other bleeding disorders family history of VWD or bleeding;
personal history of iron deﬁciency
anemia; and positive James early
bleeding score

Marcus

2011

Cohort with DTA
results for children

104

Children (age ,17 y) referred for Modiﬁed Vicenza score to include an
“other” category with pediatricevaluation of bleeding
speciﬁc bleeding questions. A
symptoms, family history of a
bleeding score $2 was considered
bleeding disorder, and/or
abnormal
abnormal coagulation studies

Belen, B.

2015

Case control

84

PBQ administration. A bleeding score $2Laboratory workup including
Children (age ,8 y) with VWD
VWF:Ag, VWF:RCo, and
(46) and control group (32) with was considered abnormal
FVIII:C
bleeding symptoms but had
normal prothrombin time, APTT,
PFA 100, VWF:Ag, VWF:RCo,
and platelet function tests

Faiz

2017

Case control

53

Laboratory workup including
Modiﬁed screening tool considered
Women (age 14-53 y): 41
CBC, ferritin, FVIII:C,
positive if 1 of 3 criteria were met:
previously untested family
VWF:Ag, and VWF:RCo
severity of heavy menstrual period,
members of VWD patients, 26
history of treatment of anemia, excess
previously diagnosed VWD
bleeding after challenges including
patients, and 27 healthy
dental surgery, and surgery and
controls
delivery

Mittal

2015

Case control

1316

MCMDM-1 VWD Bleeding
Laboratory workup including
Questionnaire. A bleeding score $4
ABO blood group,
was considered abnormal
VWF:Ag, VWF:RCo, and
FVIII:C

Laboratory workup including
VWF:RCo and VWF:Ag

Laboratory workup including
VWF:Ag, VWF:RCo, and
multimer analysis

APTT, activated partial thromboplastin time; CBC, complete blood count; DTA, diagnostic test accuracy; INR, international normalized ratio; ITEM, Test Question Analysis; PBQ, Pediatric
Bleeding Questionnaire; PFA 100, Platelet Function Assay; PT, prothrombin time; PTT, partial thromboplastin time; UMDNJ, University of Medicine and Dentistry of New Jersey.
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PBQ. Children with total bleeding
Healthy children (age ,18 y)
without a diagnosis of a chronic questionnaire scores $3 were
medical condition presenting to predicted to have VWD
a general pediatrician’s ofﬁce
for routine or sick visits, and 35
children (21 male, 14 female)
with a known diagnosis of VWD

Laboratory workup including
VWF:RCo, VWF:Ag,
FVIII:C, VWF multimers

Table 1. (continued)
Study design

No. of
patients

Year

Patient selection

Index test

Pathare

2018

Case control

96

46 patients with type 1 VWD; 46 MCMDM-1 VWD questionnaire. BleedingLaboratory workup including
VWF:Ag, VWF:RCo, and
and 50 healthy subjects with no score .2 considered signiﬁcantly
FVIII:C
abnormal
known history of bleeding or
bruising (ages 7-49 y)

Bujnicki

2011

Case control

160

Laboratory workup including
80 children (age ,11 y) with
Pediatric bleeding score modiﬁed for
VWF:Ag, VWF:RCo, and
VWF:RCo ,0.50 IU/mL, and
children based on the PBQ. A
FVIII:C
80 controls without VWD
bleeding score $1 was predictive of
VWD

Rodeghiero

2005

Case control

341

A
42 adults that are obligatory
carriers of VWD type I, 84
affected with VWD type 1, and
215 controls

standardized questionnaire, using a
bleeding score ranging from 0 (no
symptom) to 3 (hospitalization,
replacement therapy, blood
transfusion)

Reference standard

Laboratory workup including
VWF:Ag, VWF:RCo,
FVIII:C, and APTT

APTT, activated partial thromboplastin time; CBC, complete blood count; DTA, diagnostic test accuracy; INR, international normalized ratio; ITEM, Test Question Analysis; PBQ, Pediatric
Bleeding Questionnaire; PFA 100, Platelet Function Assay; PT, prothrombin time; PTT, partial thromboplastin time; UMDNJ, University of Medicine and Dentistry of New Jersey.

present the results for the low, intermediate, and high pretest probability groups.

Results
Description of studies

Identification

The initial search retrieved 5693 nonduplicate studies, of which 669
were included for full-text review. Following full-text review, we

identiﬁed 106 studies eligible for data abstraction, of which 13
answered the questions addressed in this systematic review. A list
of excluded studies is provided in supplement 2. Reasons for exclusion at full-text review were ineligible study design, study population,
or diagnostic test, sample size ,10 patients, and not enough information to determine diagnostic test accuracy for VWD (Figure 1).
All the included studies reported on the use of BATs in VWD.22-34
Table 1 summarizes general characteristics of included studies, as

Records identified through
database searching
(n = 6,216)

Eligibility

Screening

Records after duplicates removed
(n = 5,693)

Records screened
(n = 5,693)

Full-text articles assessed
for eligibility
(n = 669)

Included

Studies included in qualitative synthesis
of VWD diagnosis systematic reviews
(n = 106)

Records excluded
(n = 5,024)

Full-text articles excluded
(n = 563):
–Duplicate (n = 4)
–Incorrect study design/type (n = 150)
–Incorrect population (n = 64)
–No diagnostic tests of interest (n = 93)
–Unacceptable reference standard (n = 47)
–Not enough information to determine test for
VWD (n = 182)
–Sample size <10 pts (n = 23)

Studies included in quantitative
synthesis of Bleeding Assessment
tools Meta-Analysis
(n = 13)

Figure 1. Study ﬂow diagram for included studies.
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First author

Studies

Estimate

(95% C.I.)

TN / (FP + TN)

Bowman, M. (C, MCMDM-1) 2008
Bowman, M., (C, PBQ) 2009
Deforest, M., A., (C, Self BAT) 2015
Malec, L. M., (C, Composite score) 2016
Marcus, P. D., (C, Modified Vicenza) 2011
Philipp, C. S. (C, Questionnaire) 2008
Bidlingmaier, C. (C, ISTH Child BS) 2012

0.865
0.786
0.273
0.342
0.302
0.201
0.857

(0.812, 0.905)
(0.712, 0.845)
(0.172, 0.404)
(0.270, 0.423)
(0.219, 0.401)
(0.142, 0.278)
(0.760, 0.919)

182/210
114/145
15/55
50/146
29/96
27/134
66/77

Overall (I2 = 9744 %, P <0.001)

0.539

(0.293, 0.767)

483/863
0.34

0.53

0.72

0.92

Specificity

Studies

Estimate

(95% C.I.)

TP / (TN + FN)

Bowman, M. (C, MCMDM-1) 2008
Bowman, M., (C, PBQ) 2009
Deforest, M., A., (C, Self BAT) 2015
Malec, L. M., (C, Composite score) 2016
Marcus, P. D., (C, Modified Vicenza) 2011
Philipp, C. S. (C, Questionnaire) 2008
Bidlingmaier, C. (C, ISTH Child BS) 2012

0.938
0.833
0.778
0.681
0.875
0.833
0.783

(0.461, 0.996)
(0.369, 0.977)
(0.421, 0.944)
(0.536, 0.798)
(0.463, 0.983)
(0.523, 0.958)
(0.572, 0.907)

7/7
5/6
7/9
32/47
7/8
10/12
18/23

Overall (I2 = 0 %, P = 0.698)

0.752

(0.661, 0.826)

86/112
0.37

0.53

0.68

0.84

1

Sensitivity
Figure 2. Forest plots for sensitivity and speciﬁcity for individual studies and the pooled estimates of BAT when used as a screening tool for VWD.

well as the index and reference tests. The most common BATs used
were the Molecular and Clinical Markers for the Diagnosis and Management of Type 1 (MCMDM-1) VWD Bleeding Questionnaire; the
ISTH-BAT; the self-administered bleeding assessment tool (SelfBAT), which is the ISTH-BAT converted to a grade 4 reading level;
the Vicenza score; questionnaires based on the bleeding symptoms
especially in women; and the Pediatric Bleeding Questionnaire, which
is a modiﬁed version of the MCMDM-1VWD Bleeding Questionnaire.

Use of BATs as a screening tool for VWD
We pooled test accuracy of BATs when used as a screening tool for
VWD from 7 cohort studies, including 112 participants. Studies used
laboratory testing (VWF:Ag, VWF:RCo, FVIII:C) as a reference standard for conﬁrming VWD, with some studies also including historic
clinical diagnosis. The pooled estimates for sensitivity and speciﬁcity
were 75% (95% conﬁdence interval, 66-83) and 54% (29-77),
respectively (high certainty in the sensitivity results and moderate certainty in the speciﬁcity results). Figure 2 shows the forest plot displaying the sensitivity and speciﬁcity from individual studies and the
pooled estimates for BAT when used as a screening tool for VWD.
The complete risk of bias assessment for individual studies is included
in supplement 3.
BATs results were illustrated for 1000 patients from a low prevalence
population undergoing the test (3% prevalence, which is typically
seen in patients investigated for VWD because of a personal history
of abnormal laboratory test [eg, increased partial thromboplastin
time]), intermediate prevalence (20% prevalence which is typically
14 DECEMBER 2021 • VOLUME 5, NUMBER 23

seen in patients investigated for VWD because of a personal history
of bleeding symptoms [eg, mucocutaneous bleeding]), and high prevalence (50% prevalence, which is typically seen in patients investigated for VWD as a ﬁrst-degree relative for a patient with VWD);
absolute differences indicate a low (,20%) proportion of false negative. Overall, the test was shown to be highly sensitive and moderately
speciﬁc and the certainty of evidence was moderate to high. Table 2
shows Grading of Recommendations Assessment, Development and
Evaluation test accuracy evidence summary for BAT when used as a
screening test for VWD. The interactive summary of ﬁndings can
be accessed using the following link: https://gdt.gradepro.org/
presentations/#/isof/isof_c5b33e22-a646-4654-9f09-b820aff36c5c1569520689536?_k=eump67.

Discussion
This review presents pooled estimates of test accuracy for commonly
available BATs used as a screening test for VWD. Importantly, the certainty of evidence was moderate to high. BATs had a sensitivity and
speciﬁcity of 75% (95% conﬁdence interval, 66-83) and 54% (2977), respectively. These are overall results that include men and children; if adult women are evaluated separately, the sensitivity is much
higher (100% in some studies). The beneﬁt of using BATs is to identify
patients suspected of having VWD who may otherwise be missed
without this tool in clinic. Additionally, using a BAT will allows for the
quantiﬁcation of bleeding symptoms in patients. However, recommendations on whether to use BATs as a screening tool in clinical practice
BATs IN THE DIAGNOSIS OF VWD
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Outcome
None

Crosssectional
(cohort type
accuracy
study)
Not serious

Not serious

Serious§

Not serious

None

447 (226-686)

369 (186-566)

431 (234-614)

230 (116-353)

270 (147-384)

124 (87-169)

376 (331-413)

Pretest
probability
of 50%‡

50%

⨁⨁⨁
MODERATE

⨁⨁⨁⨁
HIGH

Test
accuracy
CoE

CoE, certainty of evidence.
*Typically seen in patients investigated for VWD because of a personal history of abnormal laboratory test (eg, increased APTT).
†Typically seen in patients investigated for VWD because of a personal history of bleeding symptoms (eg, mucocutaneous bleeding).
‡Typically seen in in patients investigated for VWD as a ﬁrst-degree relative for a patient with VWD.
§The point estimates of speciﬁcity are not homogenous, which was not explained by a priori determined analysis (eg, based on difference in risk of bias of the studies), and can be due to differences in the setting and disease prevalence.
The majority of included studies were judged to be low risk of bias for test and reference standard interpretation. Although there was unclear reporting regarding ﬂow and timing in some studies, the certainty of evidence was generally not
downgraded for risk of bias. The patient selection risk of bias was low in 7 cohort studies and high in 6 case control studies that were not included to calculate the pooled estimate.

False positives
(patients
incorrectly
classiﬁed as
having
suspected
patients)

7 studies,
863 patients

523 (284-744)

Not serious

Imprecision

True negatives
(patients
without
suspected
patients)

Not serious

Inconsistency

50 (35-68)

Not serious

Indirectness

7 (5-10)

Not serious

Risk of bias

Pretest
probability
of 20%†

False negatives
(patients
incorrectly
classiﬁed as
not having
suspected
patients)

Crosssectional
(cohort type
accuracy
study)

Publication
bias

20%

Effect per 1000 patients tested
Pretest
probability
of 3%*

3%

150 (132-165)

7 studies,
112 patients

Study
design

Prevalences

23 (20-25)

True positives
(patients
with
suspected
patients)

No. of studies
(No. of patients)

Speciﬁcity
Factors that may decrease certainty of evidence

0.75 (95% CI, 0.66-0.83)
0.54 (95% CI, 0.29-0.77)

Sensitivity

Table 2. GRADE test accuracy evidence summary for BAT when used as a screening test for VWD
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When we looked at the trend of diagnostic test accuracy based on the
date the different studies were conducted, we did not observe a clear
trend of the sensitivity and speciﬁcity that reﬂect a relation with publication time. This might be due to the use of different BATs with no
standardization of the questions asked. The changes that were
made after the ﬁrst few Vicenza-based BATs were about how long
it takes to administer and who administers it, rather than to improve
accuracy.
This review has several strengths. First, this is the ﬁrst systematic
review to comprehensively examine diagnostic test accuracy of bleeding assessment tools in both adults and children suspected of having
VWD. Second, the comprehensive and systematic approach for identifying studies makes it unlikely that relevant studies were missed.
Finally, we assessed the certainty of evidence in this area and identiﬁed sources of bias.
We note a few limitations in this comprehensive systematic review.
The pooled sensitivity and speciﬁcity estimates of the tests from this
review apply only when the test is performed alone; however, BATs
can be used as part of different diagnostic strategies to inform clinical
decision-making.

Conclusion
This comprehensive systematic review is the ﬁrst to synthesize and
evaluate the accuracy of BATs as a screening tool for the diagnosis

of VWD in adults and children. Estimates of sensitivity and speciﬁcity
from this review were used to inform evidence-based recommendations for a clinical practice guideline. Prevalence or pretest probability
of VWD in a population is essential to consider when making clinical
decisions about relying on the BAT results to rule in or rule out VWD
diagnosis.
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